StocksRunner logo
mail
search
 
menu
 
Abeona Therapeutics
6.56
-4.51%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

ABEO ABEO Badge

 

Abeona Therapeutics

$6.56

 
-$0.31 | -4.51%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
Open
$ 6.96
 
 
MKT CAP
$ 322.81M
 
High
$ 7.08
 
 
VOL
$ 1.62M
 
Low
$ 6.55
 
 
AVG VOL
$ 2.11M
 
 
 

Chart

 
 

5.12

5.7

5.7

4.4

 
 
1year
6month
3month
1month
 
ABEO Latest Headlines +
 
 
 
StocksRunner

Explore our ABEO Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored ABEO Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our ABEO Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner
Overview
 
StocksRunner
Trending
 
StocksRunner
Screener
 
StocksRunner
Ideas
 
StocksRunner
Top Rated
 
StocksRunner
Momentum
 
StocksRunner
Earnings
 
 

Most Trending

 
 
 
Top Banner
 
  Overview  
  
  Analysis  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

ABEO ABEO Badge

 

Abeona Therapeutics

$6.56

 
-$0.31 | -4.51%
 

 

Chart

 
 

5.12

5.7

5.7

4.4

 
 
1year
6month
3month
1month
 
 
 
 

ABEO Latest Headlines

 
 
 

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease. ) stock traded higher on Wednesday.The Food and Drug Administration (FDA) on Tuesday approved Abeona’.s Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets also known as pz-cel as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic .Zevaskyn is the only FDA-approved product to treat RDEB wounds.Zevaskyn consists of a patient&#

 

Wed Apr 30, 2025

 
Activity
Momentum

Abeona Stock Surges to 52-Week High: Whats Behind The Move?. ) shares are trading higher on Wednesday on possible continued strength after the Food and Drug Administration (FDA) announced approval for The stock hit a new 52-week high of $7.32 today ...

 

Wed Apr 30, 2025

 
Activity
Momentum

ABEO: Zevaskyn™ Approved by FDA. Raising Valuation to $11. By Business UpdateZevaskyn™ Approved by FDAOn April 29 2025 Abeona Therapeutics Inc. (NASDAQ:ABEO) announced that the United States Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic epidermolysis osa (RDEB). The company indicated that the commercial launch will commence in the third quarter of 2025. Zevaskyn will have a wholesale

 

Wed Apr 30, 2025

 
Activity
Potential

Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy. The United States Food and Drug Administration (FDA) on Tuesday approved ) Zevaskyn (prademagene zamikeracel) gene-modified cellular sheets also known as pz-cel as the first and only autologous cell-based gene therapy for wounds in adult and pediatric patients with recessive dystrophic .RDEB isa severe genetically inherited skin disorder characterized by blistering and skin fragility often presenting at birth.Zevaskyn is t

 

Tue Apr 29, 2025

 
Activity

Abeona spikes on FDA nod for gene therapy.

 

Tue Apr 29, 2025

 
Activity
Momentum

Abeona Therapeutics: pz-cel Has Massive Potential For RDEB Patients.

 

Mon Apr 21, 2025

 
Potential

Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside.

 

Mon Apr 14, 2025

 
Potential
Potential

 
 
 
 
 
StocksRunner

Discover ABEO Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ABEO. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our ABEO Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ABEO Stock trends

ABEO Stock performance

ABEO Stock analysis

ABEO investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 
Post ×
 
0/666
joker